Flow cytometric evaluation of bladder cancer: recommendations of the NCI flow cytometry network for bladder cancer

R. L. Aamodt, J. S. Coon, A. Deitch, Ralph W deVere White, L. G. Koss, M. R. Melamed, R. S. Weinstein, L. L. Wheeless

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The National Cancer Institute-supported Flow Cytometry Network for Bladder Cancer concluded that when properly used, DNA flow cytometry of bladder irrigation specimens can be a clinically useful laboratory procedure to monitor patients with bladder cancer. It recommended the use of this technique in managing patients with low-stage disease, particularly flat carcinoma in situ. The method has limited value in managing patients with high-stage (i.e., muscle-invasive) carcinoma; it is not recommended for screening subjects in the absence of a clinical suspicion of or a history of bladder tumors. DNA histograms alone are not sufficient for diagnosis or clinical action but require correlation with other clinical information. Bladder irrigation specimens collected during cystoscopy or by vigorous barbotage via a number 18 Foley catheter may be processed for flow cytometric analyses. Criteria for sampling adequacy have been established and are presented in this report. Optimal results are obtained with fresh specimens that are stained and examined promptly after collection. Preservation procedures are described for cases in which fresh specimens cannot be evaluated. Used with appropriate quality-control measures, commercially available flow cytometers can provide clinically useful information. Staining protocols using propidium iodide are recommended by the Network. Staining protocols are described for isolated nuclei and whole cells (see Appendix). The presence of bladder cancer is signaled by the identification of cell populations with clearly aneuploid DNA content. Quality-control measures and issues of inter- and intralaboratory differences in histogram configuration and analysis must be considered in the interpretation of results. Although the Network participants recognize the potential value of additional markers, these were not evaluated.

Original languageEnglish (US)
Pages (from-to)63-67
Number of pages5
JournalWorld Journal of Urology
Volume10
Issue number1
DOIs
StatePublished - Feb 1992

Fingerprint

Urinary Bladder Neoplasms
Flow Cytometry
Quality Control
DNA
Urinary Bladder
Staining and Labeling
Cystoscopy
National Cancer Institute (U.S.)
Propidium
Carcinoma in Situ
Aneuploidy
Cell Nucleus
Catheters
Carcinoma
Muscles
Population

ASJC Scopus subject areas

  • Urology

Cite this

Flow cytometric evaluation of bladder cancer : recommendations of the NCI flow cytometry network for bladder cancer. / Aamodt, R. L.; Coon, J. S.; Deitch, A.; deVere White, Ralph W; Koss, L. G.; Melamed, M. R.; Weinstein, R. S.; Wheeless, L. L.

In: World Journal of Urology, Vol. 10, No. 1, 02.1992, p. 63-67.

Research output: Contribution to journalArticle

Aamodt, R. L. ; Coon, J. S. ; Deitch, A. ; deVere White, Ralph W ; Koss, L. G. ; Melamed, M. R. ; Weinstein, R. S. ; Wheeless, L. L. / Flow cytometric evaluation of bladder cancer : recommendations of the NCI flow cytometry network for bladder cancer. In: World Journal of Urology. 1992 ; Vol. 10, No. 1. pp. 63-67.
@article{32e210c635d64c4d8b4a24bc8d70cbac,
title = "Flow cytometric evaluation of bladder cancer: recommendations of the NCI flow cytometry network for bladder cancer",
abstract = "The National Cancer Institute-supported Flow Cytometry Network for Bladder Cancer concluded that when properly used, DNA flow cytometry of bladder irrigation specimens can be a clinically useful laboratory procedure to monitor patients with bladder cancer. It recommended the use of this technique in managing patients with low-stage disease, particularly flat carcinoma in situ. The method has limited value in managing patients with high-stage (i.e., muscle-invasive) carcinoma; it is not recommended for screening subjects in the absence of a clinical suspicion of or a history of bladder tumors. DNA histograms alone are not sufficient for diagnosis or clinical action but require correlation with other clinical information. Bladder irrigation specimens collected during cystoscopy or by vigorous barbotage via a number 18 Foley catheter may be processed for flow cytometric analyses. Criteria for sampling adequacy have been established and are presented in this report. Optimal results are obtained with fresh specimens that are stained and examined promptly after collection. Preservation procedures are described for cases in which fresh specimens cannot be evaluated. Used with appropriate quality-control measures, commercially available flow cytometers can provide clinically useful information. Staining protocols using propidium iodide are recommended by the Network. Staining protocols are described for isolated nuclei and whole cells (see Appendix). The presence of bladder cancer is signaled by the identification of cell populations with clearly aneuploid DNA content. Quality-control measures and issues of inter- and intralaboratory differences in histogram configuration and analysis must be considered in the interpretation of results. Although the Network participants recognize the potential value of additional markers, these were not evaluated.",
author = "Aamodt, {R. L.} and Coon, {J. S.} and A. Deitch and {deVere White}, {Ralph W} and Koss, {L. G.} and Melamed, {M. R.} and Weinstein, {R. S.} and Wheeless, {L. L.}",
year = "1992",
month = "2",
doi = "10.1007/BF00186094",
language = "English (US)",
volume = "10",
pages = "63--67",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Flow cytometric evaluation of bladder cancer

T2 - recommendations of the NCI flow cytometry network for bladder cancer

AU - Aamodt, R. L.

AU - Coon, J. S.

AU - Deitch, A.

AU - deVere White, Ralph W

AU - Koss, L. G.

AU - Melamed, M. R.

AU - Weinstein, R. S.

AU - Wheeless, L. L.

PY - 1992/2

Y1 - 1992/2

N2 - The National Cancer Institute-supported Flow Cytometry Network for Bladder Cancer concluded that when properly used, DNA flow cytometry of bladder irrigation specimens can be a clinically useful laboratory procedure to monitor patients with bladder cancer. It recommended the use of this technique in managing patients with low-stage disease, particularly flat carcinoma in situ. The method has limited value in managing patients with high-stage (i.e., muscle-invasive) carcinoma; it is not recommended for screening subjects in the absence of a clinical suspicion of or a history of bladder tumors. DNA histograms alone are not sufficient for diagnosis or clinical action but require correlation with other clinical information. Bladder irrigation specimens collected during cystoscopy or by vigorous barbotage via a number 18 Foley catheter may be processed for flow cytometric analyses. Criteria for sampling adequacy have been established and are presented in this report. Optimal results are obtained with fresh specimens that are stained and examined promptly after collection. Preservation procedures are described for cases in which fresh specimens cannot be evaluated. Used with appropriate quality-control measures, commercially available flow cytometers can provide clinically useful information. Staining protocols using propidium iodide are recommended by the Network. Staining protocols are described for isolated nuclei and whole cells (see Appendix). The presence of bladder cancer is signaled by the identification of cell populations with clearly aneuploid DNA content. Quality-control measures and issues of inter- and intralaboratory differences in histogram configuration and analysis must be considered in the interpretation of results. Although the Network participants recognize the potential value of additional markers, these were not evaluated.

AB - The National Cancer Institute-supported Flow Cytometry Network for Bladder Cancer concluded that when properly used, DNA flow cytometry of bladder irrigation specimens can be a clinically useful laboratory procedure to monitor patients with bladder cancer. It recommended the use of this technique in managing patients with low-stage disease, particularly flat carcinoma in situ. The method has limited value in managing patients with high-stage (i.e., muscle-invasive) carcinoma; it is not recommended for screening subjects in the absence of a clinical suspicion of or a history of bladder tumors. DNA histograms alone are not sufficient for diagnosis or clinical action but require correlation with other clinical information. Bladder irrigation specimens collected during cystoscopy or by vigorous barbotage via a number 18 Foley catheter may be processed for flow cytometric analyses. Criteria for sampling adequacy have been established and are presented in this report. Optimal results are obtained with fresh specimens that are stained and examined promptly after collection. Preservation procedures are described for cases in which fresh specimens cannot be evaluated. Used with appropriate quality-control measures, commercially available flow cytometers can provide clinically useful information. Staining protocols using propidium iodide are recommended by the Network. Staining protocols are described for isolated nuclei and whole cells (see Appendix). The presence of bladder cancer is signaled by the identification of cell populations with clearly aneuploid DNA content. Quality-control measures and issues of inter- and intralaboratory differences in histogram configuration and analysis must be considered in the interpretation of results. Although the Network participants recognize the potential value of additional markers, these were not evaluated.

UR - http://www.scopus.com/inward/record.url?scp=0026559468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026559468&partnerID=8YFLogxK

U2 - 10.1007/BF00186094

DO - 10.1007/BF00186094

M3 - Article

AN - SCOPUS:0026559468

VL - 10

SP - 63

EP - 67

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 1

ER -